HK inno N
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
HK inno N makes prescription medicines, including a treatment for peptic ulcers called K-CAB, Korea's thirtieth domestically developed new drug, as well as health-and-beauty drinks such as Condition and Hericium water.
Its prescription medicines reach patients through hospitals and clinics in Korea and through licensing and distribution partners in markets including China, the United States, India, and Latin America. Listed on KOSDAQ, Korea's tech and small-cap board, the company earns the large majority of its revenue from its prescription-medicine division, with its health-and-beauty segment making up a much smaller share.
Summary is AI-generated and may contain errors · figures from DART filings
HK inno N was acquired by Korean cosmetics and pharmaceutical group Hankook Kolmar in the filing's stated period, and was previously spun off from CJ CheilJedang as a separate legal entity.
HK inno N in five facts
What does HK inno N do?
HK inno N makes prescription medicines, including a treatment for peptic ulcers called K-CAB, Korea's thirtieth domestically developed new drug, as well as health-and-beauty drinks such as Condition and Hericium water.
Where is HK inno N listed and in which sector?
HK inno N (Korean name: HK이노엔) trades under KRX code 195940 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is HK inno N?
Its market capitalisation was US$746.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were HK inno N's latest annual revenue and operating profit?
For fiscal year 2025, HK inno N reported revenue of US$802.4M, operating profit of US$83.7M and net income of US$57.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 18.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Oct 2
- DisclosureSep 16
- Operating results (preliminary) (fair disclosure)
HK inno N filed provisional (unaudited) separate results for Q2 2026: revenue of US$185M (+1.6% year on year), operating profit of US$20.8M (+53.6% year on year) and net income of US$9.48M (+13.6% year on year).
Earnings · Jul 29 - Operating results (preliminary) (fair disclosure)
HK inno N filed provisional (unaudited) separate results for Q1 2026: revenue of US$176M (+4.6% year on year), operating profit of US$22.5M (+30.8% year on year) and net income of US$17.6M (+48.9% year on year).
Earnings · Apr 28 - [Amended] Cash/in-kind dividend decision
HK inno N updated its declared cash dividend of US$0.28 per share, equal to about 0.8% of the recent share price.
Dividend · Apr 24 · 2 versions - Operating results (preliminary) (fair disclosure)
HK inno N filed provisional (unaudited) separate results for Q4 2025: revenue of US$200M (+23.8% year on year), operating profit of US$27.5M (+64.5% year on year) and net income of US$19M (+44.3% year on year).
Earnings · Feb 10